**Tivic Health Systems, Inc. Announces Strategic Shift and Financial Results in Form 10-K Filing**
Tivic Health Systems, Inc., a biopharmaceutical company, filed its annual report on Form 10-K, outlining a significant strategic transformation during fiscal year 2025. The company pivoted from a diversified bioelectronic medical device company to a biopharmaceutical company focused on its lead program, Entolimod, a recombinant TLR5 agonist. This shift included securing exclusive worldwide license rights to Entolimod and establishing Velocity Bioworks as a contract development and manufacturing organization (CDMO) subsidiary. Concurrently, Tivic ceased sales of its ClearUP sinus device and suspended prescription bioelectronic product development to concentrate resources on Entolimod development.
The company's financial performance for the year ended December 31, 2025, showed a net loss of $8.9 million, compared to a net loss of $5.7 million for the previous year. Research and development expenses increased to $3.1 million, driven by biopharma activities and the establishment of Velocity Bioworks. Selling, general, and administrative expenses also rose to $4.8 million, reflecting increased personnel costs, legal expenses related to strategic transactions, and corporate costs. The company's cash and cash equivalents stood at $12.6 million as of December 31, 2025.
Key operational developments included the acquisition of manufacturing and development assets from Scorpius Biomanufacturing, leading to the creation of Velocity Bioworks. This acquisition was supported by a financing package of $16 million in debt and up to $75 million in preferred convertible equity. Velocity Bioworks demonstrated a 200-fold manufacturing scale-up for Entolimod, meeting drug release specifications. The company also engaged with government agencies to advance discussions on federal funding for future testing and potential Strategic National Stockpile purchases.
Looking ahead, Tivic Health is focused on advancing Entolimod through regulatory approval for acute radiation syndrome and expanding its designations into oncology-related conditions. The company anticipates needing additional capital to fund its operations, including research and development, clinical trials, and potential commercialization efforts. Management acknowledges that the company's cash and financial resources may be insufficient to meet its anticipated needs for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
About Tivic Health Systems, Inc.
Tivic Health Systems develops non-invasive bioelectronic devices and biologics to treat immune and autonomic nervous system disorders. Its core products include FDA-approved sinus relief devices and advanced vagus nerve stimulation platforms. The company focuses on innovative, low-risk therapies for conditions like sinus pain, inflammation, and radiation syndrome, leveraging proprietary technology, strong IP, and regulatory pathways to address large healthcare markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.